2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Lipid Metabolism
  5. Hypercholesterolemia

Hypercholesterolemia

Hypercholesterolemia is a form of hyperlipidemia characterized by elevated levels of cholesterol in the blood, primarily due to increased low-density lipoprotein (LDL) particles, and is a major modifiable risk factor for atherosclerosis and cardiovascular disease. It can be classified as primary (genetic, such as familial hypercholesterolemia) or secondary (resulting from conditions like diabetes, hypothyroidism, or renal disease). Cholesterol is transported in the bloodstream via lipoproteins, with dietary cholesterol absorbed in the intestine and packaged into chylomicrons, which are then processed through the lymphatic system and degraded in peripheral tissues by lipoprotein lipase, ultimately delivering remnants to the liver. The condition has become increasingly treatable with statins, and diagnostic thresholds have been progressively lowered due to improved understanding of its role in cardiovascular pathology.

Hypercholesterolemia (18):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14668
    Lomitapide mesylate 202914-84-9 99.61%
    Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8+ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia.
    Lomitapide mesylate
  • HY-W145516
    Guar gum 9000-30-0 98.0%
    Guar gum is an orally active nonionic galactomannan polysaccharide. It is present in the endosperm of Cyamopsis tetragonolobus seeds. Guar gum reduces cholesterol levels, regulates body weight, and acts as a thickener and viscosity modifier by forming hydrogen-bonded aqueous solutions. It serves as a rate-controlling excipient in compound delivery systems, and finds applications in the food, tissue engineering, nanosensing and industrial fields.
    Guar gum
  • HY-N2382
    Polyphyllin H 81917-50-2 99.89%
    Polyphyllin H is a steroidal saponin. Polyphyllin H is isolated from Paris polyphylla. Polyphyllin H potently inhibits the activities of CYP1A2 (IC50 = 6.44 μM, competitive), CYP2D6 (IC50 = 13.88 μM, competitive) and CYP3A4 (IC50 = 4.52 μM, non-competitive, time-dependent). Polyphyllin H downregulates the expression of ABCB1 and ABCC3. Polyphyllin H binds to membrane cholesterol and disrupts lipid raft structures. Polyphyllin H restores the sensitivity of paclitaxel-resistant breast cancer cells to paclitaxel.
    Polyphyllin H
  • HY-W015806
    3-Pyridineacetic acid 501-81-5 99.98%
    3-Pyridineacetic acid is an orally active nicotinic acid analog. 3-Pyridineacetic acid enhances cholesterol oxidation in rat liver mitochondria. 3-Pyridineacetic acid inhibits Triton-induced hypercholesterolemia in rats. 3-Pyridineacetic acid can be used in research related to hypercholesterolemia.
    3-Pyridineacetic acid
  • HY-179591
    BGT-002 2127387-94-2 99.35%
    BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research.
    BGT-002
  • HY-W1126955
    Enlicitide (decanoate) 2861205-06-1
    Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease.
    Enlicitide (decanoate)
  • HY-N18304
    Brutieridin 1162664-57-4
    Brutieridin (Compound 1) is a flavanone glycoside that can be isolated from the juice of bergamot (Citrus bergamia). Brutieridin reduces the level of NPC1L1 in intestinal epithelial cells. Brutieridin decreases cholesterol uptake by intestinal epithelial cells. Brutieridin reduces HMGR activity. Brutieridin can be used in the research of hypercholesterolemia.
    Brutieridin
  • HY-122439
    Lovastatin acid 75225-51-3
    Lovastatin acid (Mevinolinic acid; MSD803), an active metabolite of Lovastatin (HY-N0504), is a potent competitive HMG-CoA reductase inhibitor with a Ki of 0.6 nM. Lovastatin acid acts as a competitive inhibitor with respect to substrate HMG-CoA, interfering cholesterol synthesis. Lovastatin acid can be used for the research of hypercholesterolemia.
    Lovastatin acid
  • HY-10357
    MK-2206 free base 1032349-93-1
    MK-2206 free base is an orally active pan-AKT inhibitor, with IC50 values of 8 nM, 12 nM and 65 nM against AKT1, AKT2 and AKT3, respectively. MK-2206 free base inhibits the Akt/mTOR signaling pathway and reduces the levels of downstream GSK3β and Mcl-1 via proteasomal degradation. MK-2206 free base induces G1-phase cell cycle arrest, apoptosis, epithelial-mesenchymal transition, fibroblast activation and extracellular matrix deposition. MK-2206 free base causes transient hyperglycemia and hyperinsulinemia in animals. MK-2206 free base can be used in research related to solid tumors, renal fibrosis and hypercholesterolemia.
    MK-2206 free base
  • HY-182475
    SQ 31906 free base 81131-74-0
    SQ 31906 free base is the 3α-hydroxy isomer and metabolite of Pravastatin (HY-B0165). SQ 31906 free base forms via non-enzymatic reaction under acidic conditions. Pravastatin is used in hypercholesterolemia research.
    SQ 31906 free base
  • HY-182257
    Atorvastatin (lysine) 609843-23-4
    Atorvastatin lysine is an inhibitor of HMG-CoA reductase. Atorvastatin lysine can be used to study hypercholesterolemia and mixed hyperlipidemia.
    Atorvastatin (lysine)
  • HY-181876
    F44-S101 3124701-00-1
    F44-S101 is an orally active, potent, and selective gut-restricted FXR antagonist with an IC50 of 0.48 μM and lipid-lowering activity. F44-S101 selectively antagonizes intestinal FXR, feedback-activates hepatic FXR, promotes cholesterol metabolism and reduces lipid accumulation. F44-S101 decreases total cholesterol, triglyceride and low-density lipoprotein cholesterol levels. F44-S101 can be used in studies related to hyperlipidemia.
    F44-S101
  • HY-19201
    Axitirome 156740-57-7
    Axitirome (CGS 26214) is a potent, liverselective TRβ receptor agonist and thyromimetic agent. Axitirome has demonstrated cholesterol-lowering activity.
    Axitirome
  • HY-106106
    Tiqueside 99759-19-0
    Tiqueside (CP‐88,818) is an orally active cholesterol absorption inhibitor. Tiqueside inhibits absorption of both dietary cholesterol and endogenous cholesterol excreted into the intestinal lumen via the bile. Tiqueside can be used in the research of hypercholesterolemia.
    Tiqueside
  • HY-105020
    Derpanicate 99518-29-3
    Derpanicate is a Nicotinic acid (HY-B0143) ester. Derpanicate has antihypercholesterolaemic and/or vasodilating effects.
    Derpanicate
  • HY-149310
    Dim16 2743448-32-8
    Dim16 is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 can be used in research related to hypercholesterolemia.
    Dim16
  • HY-149310A
    Dim16 hydrochloride 2743448-41-9
    Dim16 hydrochloride is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 hydrochloride disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 hydrochloride can be used in research related to hypercholesterolemia.
    Dim16 hydrochloride
  • HY-181520
    ABCA1 inducer 3 2681270-30-2
    ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid-modulating agent. ABCA1 inducer 3 increases ABCA1 expression. ABCA1 inducer 3 upregulates hepatic Abcg5 and Abcg8 mRNA expression. ABCA1 inducer 3 promotes cholesterol efflux. ABCA1 inducer 3 improves hyperlipidemia.
    ABCA1 inducer 3